ATAI Life Sciences NV held its annual general meeting of shareholders on May 15, 2025. The shareholders approved the adoption of the Dutch statutory annual accounts for fiscal year 2024. Deloitte & Touche LLP and Deloitte Accountants B.V. were appointed as the external auditor for fiscal year 2025. Members of the supervisory and management boards were released from liability for the exercise of their duties during fiscal year 2024. The authorization of the management board to issue shares and grant rights to subscribe for shares was extended. The management board's authorization to limit and exclude pre-emption rights was also extended. Additionally, the authorization of the management board to acquire shares or depositary receipts for such shares in the company's capital was extended.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。